Skip to content

PEG-MGF

A PEGylated version of MGF with extended half-life for systemic muscle growth and recovery effects.

DPreliminaryLimited Data
Last updated 22 citations
TL;DR

PEG-MGF is a lab-made fragment of a muscle-repair signal, with a polymer attached so it lasts longer in the body. It is sold for muscle growth and recovery, and it has never been tested in a human clinical trial of any kind — no dosing study, no efficacy study, nothing. Two things undercut the story behind it. The fragment is supposed to work through a receptor other than the usual IGF-1 receptor, but nobody has found that receptor in over twenty years. And when two pharmaceutical companies tried to reproduce the muscle-cell effect the whole idea rests on, they could not, across four different experiments. It is also banned in sport and detectable in urine and blood tests.

What is PEG-MGF?

PEG-MGF is a PEGylated form of Mechano Growth Factor where a polyethylene glycol molecule is attached to the synthetic E-domain peptide to increase stability and slow clearance. The usual claim is that this extends the half-life from minutes to several hours, and that claim should not be repeated as fact: no half-life has ever been measured for PEG-MGF, for native MGF, or for the isolated E-domain peptide, in any species. The only source in the indexed literature connecting MGF to a half-life at all is a 2001 Goldspink review saying it is shorter than that of liver-derived IGF-1 — no figure, no species, no assay — and the 2026 review that covers PEG-MGF states plainly that its half-life is not reported. PEGylation reliably slows clearance of the molecules it has been tested on, so longer exposure is a reasonable expectation; the specific numbers in circulation are not measurements.

What PEG-MGF Is Investigated For

PEG-MGF is a PEGylated synthetic form of the mechano growth factor E-domain peptide, marketed in bodybuilding and recovery contexts for systemic muscle growth, satellite-cell activation, and anti-inflammatory and tissue-protective effects in muscle injury. The underlying biology — endogenous MGF expression in mechanically loaded muscle, satellite-cell proliferation, macrophage modulation, and animal injection studies showing benefit in injury models — is moderately supported by Goldspink's original work and follow-up animal studies. But PEG-MGF itself has no published human clinical trial of any kind: no human pharmacokinetic data, no efficacy trial in any population, and a 2014 study (Fornaro et al.) reporting that the isolated E-peptide had no apparent effect on myoblasts or muscle stem cells in isolation, directly contradicting the mechanistic premise behind commercial use. Anti-PEG antibody concerns with repeated exposure and the explicit WADA S2.3 prohibition for athletes add further caveats. The honest framing: animal-model rationale and extrapolation, no human trial data for the pegylated synthetic product, and detection methods now exist for anti-doping controls.

Systemic muscle growth and recovery via satellite cell activation
Preliminary30%
Longer exposure than native MGF — expected from PEGylation, but never measured for either molecule in any species
Limited15%
Effects on inflammation and tissue protection in muscle injury — direction contested; the one overexpression study delayed macrophage resolution and raised inflammatory markers
Limited15%
Potential cardioprotective and neuroprotective properties
Preliminary30%

History & Discovery

PEG-MGF is the pegylated synthetic form of Mechano Growth Factor, a locally acting splice variant of insulin-like growth factor 1 (IGF-1Ec) identified in the early 1990s by Geoffrey Goldspink and colleagues at the Royal Free Hospital in London. Goldspink's group was investigating why skeletal muscle responds to mechanical loading and found that mechanical stress triggered alternative splicing of the IGF-1 gene, producing a transcript with a distinctive C-terminal extension — the 'E-domain' — that differed from the systemically circulating liver-derived IGF-1. This splice variant was shown to be released locally in damaged and mechanically loaded muscle, where it appeared to activate satellite (muscle stem) cells and promote the early proliferative phase of muscle repair before the tissue transitions to differentiation. Goldspink coined the 'mechano growth factor' name to reflect this mechanical-load-dependent expression. Native MGF is widely described as having a very short functional half-life, which fits its proposed role as a local paracrine signal rather than a circulating hormone — but the figure has never been measured. The sole indexed source is Goldspink's own 2001 review, which says only that MGF has a shorter half-life than liver-type IGF-1 in the unbound state; no number, species or assay accompanies it. The one piece of hard data pointing the other way comes from an anti-doping laboratory that tested peptide confiscated from the market and reported that the stabilised analogue MGF R23H has good in vitro plasma stability. PEG-MGF was developed as a research-chemical product by attaching a polyethylene glycol polymer to the synthetic E-domain peptide, a standard pharmaceutical stabilization approach that extends half-life by reducing renal clearance and proteolytic degradation. This migration into the research-chemical and bodybuilding market occurred in the 2000s, well before any controlled human study of the synthetic form. Critically, PEG-MGF has never been developed through a regulated pharmaceutical pathway: there is no FDA-registered PEG-MGF product, no published Phase I human pharmacokinetic data for the pegylated synthetic form, and no controlled efficacy trial in any human population. Most of the biological rationale cited for its use is extrapolated from Goldspink's original work on native MGF expression in exercised muscle and from animal models of injected MGF in injury contexts. A 2026 Frontiers in Endocrinology review by Dominikowski and colleagues (PMID 42395176) mapping the performance-enhancing GH-IGF1-axis peptide landscape names PEG-MGF explicitly as one of the IGF-1 analogues encountered in unregulated self-administration, tiers the class by evidence quality, and provides a clinician-facing framework for assessing patients who present already on these agents — an unusually current peer-reviewed anchor for the 'clinically encountered, no evidence base, WADA-prohibited' framing this page carries.

How It Works

PEG-MGF is a longer-lasting version of the muscle repair signal MGF. The PEG coating protects it from breakdown, allowing it to circulate throughout the body and support muscle recovery systemically rather than just locally.

MGF (IGF-1Ec) is a splice variant of IGF-1 produced in response to mechanical stress. Its C-terminal E-domain peptide is proposed to activate muscle satellite (stem) cells through a receptor other than IGF-1R. That proposal traces to a single 2002 experiment in which blocking IGF-1R with an antibody did not abolish the E-domain's effect, which indicated a different receptor without identifying one — and more than two decades later, none has been named. The negative half has since been reinforced independently, including by small-interfering-RNA work showing that silencing IGF-1R, the insulin receptor, or the hybrid receptor left the E-peptide's activity intact. The positive half is the problem: that the peptide activates satellite cells at all failed an industry replication attempt. PEGylation of this E-domain peptide is expected to reduce renal clearance and protease degradation, although no half-life has been measured for the pegylated peptide or for the native one. MGF alters inflammatory cytokine expression and macrophage dynamics during muscle injury, but not in the direction the anti-inflammatory framing implies: overexpression delayed macrophage resolution and upregulated inflammatory markers without changing regeneration outcomes. Cardioprotective effects through inhibition of apoptosis after myocardial infarction are better supported. The E-domain also shows neuroprotective activity in ischemia models. The receptor picture turns entirely on which molecule is meant, and the distinction matters for anyone buying a research-chemical vial they cannot assay. Independent receptor work found that full-length MGF does activate IGF-1R, reaching a similar maximum to IGF-1 at high equimolar concentrations but roughly nine-fold less potently (EC50 7.83 nmol/L against 0.86 nmol/L), and also activates both insulin receptor isoforms, with IR-B stimulation actually exceeding that of insulin itself. The isolated 24-amino-acid E-peptide and its stabilised analogue activated none of these receptors. PEG-MGF is built from the E-peptide, so the reassuring reading is that it should not drive IGF-1R signalling — while the same fact removes the mechanism by which it would be expected to do anything. Downstream signalling is contested too: one group reported ERK1/2 activation without Akt, and the replication attempt found neither.

Evidence Snapshot

Overall Confidence25%

Human Clinical Evidence

No clinical trials of PEG-MGF itself. Human work is limited to endogenous MGF expression after resistance exercise, and even that is thinner than it is usually described: in the resistance-training study the muscle proteins and messenger RNAs of interest were not systematically influenced by exercise or training, the single exception being MGF messenger RNA, which rose after resistance exercise in older men only and only before the training period. One study of PEGylated recombinant IGF-1 (not MGF specifically) showed extended half-life in humans.

Animal / Preclinical

Moderate for native MGF. The animal record is more mixed than it is usually presented. In the macrophage-depletion model, MGF injection did not protect muscle fibre regeneration; it reduced fibrosis in contused muscle, which is a narrower result than the paper's title suggests. In the overexpression study the inflammatory effect runs the opposite way to the anti-inflammatory framing often attached to MGF: forced MGF expression delayed the resolution of macrophages, particularly the pro-inflammatory phenotype, coincided with upregulated inflammatory markers, and did not obviously change regeneration outcomes. Clearer positives come from the cardiac infarction and ALS models, though the ALS work used plasmid delivery rather than peptide injection. PEG-MGF-specific animal data remain limited.

Mechanistic Rationale

Weak, and weaker than this page previously claimed. The central mechanism — that the isolated E-domain peptide activates satellite cells through a receptor other than IGF-1R — rests on an inference from blocking experiments; no such receptor has been identified in more than two decades, and an industry replication attempt across four assays and three cell types failed to reproduce the proliferative effect at all. Independent receptor pharmacology shows the isolated E-peptide does not activate IGF-1R, the insulin receptor, or hybrid receptors, which supports the negative half of the claim while leaving the positive half unsupported. No pharmacokinetics have been measured for the pegylated peptide in any species.

Research Gaps & Open Questions

What the current literature has not yet settled about PEG-MGF:

  • 01Basic pharmacokinetics in any species, not just humans — no published study has characterized absorption, distribution, half-life or clearance of synthetic PEG-MGF, of native MGF, or of the isolated E-domain peptide. The 2026 review covering the molecule states directly that its half-life is not reported, which makes every circulating figure for it an inference from PEGylation generally rather than a measurement.
  • 02Efficacy in any human endpoint — no controlled trial has tested PEG-MGF for muscle growth, recovery, injury repair, or any other endpoint in humans. All efficacy claims rest on extrapolation from native-MGF animal models or from MGF expression studies in exercised human muscle.
  • 03Whether the isolated E-domain peptide actually produces the satellite-cell activation effects attributed to it — a 2014 study (Fornaro and colleagues) reported that the isolated E-peptide had no apparent effect on myoblasts or primary muscle stem cells, contradicting earlier findings and raising real questions about the fragment's biological activity in isolation.
  • 04Long-term safety of PEG exposure — anti-PEG antibody formation and accelerated blood clearance phenomena are documented concerns for pegylated biologics; whether these arise with PEG-MGF specifically has not been characterized.
  • 05Tumor biology interactions — the theoretical cancer-relevant signaling overlap (satellite-cell proliferation, angiogenic modulation, IGF-family activity) has not been quantified in long-duration carcinogenicity or pharmacovigilance data.
  • 06Comparative characterization against native MGF, full-length IGF-1Ec, IGF-1 LR3, and IGF-1 DES for any defined biological endpoint in a controlled setting.

Forms & Administration

SC or IM injection. Typical research dose: 200mcg, 2-3 times per week. Can be injected systemically rather than site-specifically. All injectable peptides should only be administered under the guidance of a qualified healthcare provider. Never self-administer without clinician oversight.

Dosing & Protocols

The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.

Typical Range

There is no published human dose-ranging data for PEG-MGF specifically; the commonly cited doses are entirely drawn from research-chemical and bodybuilding-community practice rather than clinical studies. The most frequently referenced range is 100–500 mcg per injection, with 200 mcg per dose being a typical mid-range number in circulated protocols. These doses are extrapolated partly from native MGF animal studies scaled by body weight and partly from analogous dosing of other IGF-1-family peptides; they should not be read as validated.

Frequency

Circulated protocols typically describe 2–3 injections per week, a cadence justified by an assumed multi-hour half-life for PEG-MGF against an assumed minutes-long one for native MGF — neither of which has been measured in any species. Post-workout dosing is commonly recommended on the rationale that mechanical muscle damage creates the biological context in which MGF signaling is naturally active, though this rationale rests on native MGF biology rather than on any study of synthetic PEG-MGF timing. Daily dosing is not typical; it would likely saturate receptor signaling without pharmacodynamic benefit given the pegylated pharmacokinetics.

Timing Considerations

Time of day

Assumed to be less tightly tied to individual training sessions than standard MGF, on the premise that pegylation lengthens exposure. No pharmacokinetic study has tested that premise for either molecule.

Relative to meals

Commonly paired with a post-workout meal when timed around training, but the wider dosing window makes meal timing less critical than with standard MGF.

Relative to exercise

Post-workout injection is the standard pattern, typically 1–2 times weekly on training days or the day after. The rationale offered is that, unlike standard MGF, PEG-MGF need not be injected within minutes of training because its circulating exposure covers the post-exercise repair window. No measured half-life exists for either form, so this is an assumption rather than a pharmacokinetic finding.

Cycle Length

Commonly discussed cycles run 4–6 weeks on followed by an equivalent break. There is no evidence-based rationale for any specific cycle length — the convention is a generic research-chemical precaution rather than a validated practice. No long-duration human data exists to inform continuous vs. cycled use, long-term receptor effects, or any downstream consequences of sustained E-domain peptide exposure.

Protocol Notes

PEG-MGF is supplied as a lyophilized powder, typically 2 mg per vial, and is reconstituted in bacteriostatic water. A 2 mg vial in 1 mL yields 2,000 mcg/mL, making 200 mcg roughly 0.1 mL or 10 units on an insulin syringe. Both subcutaneous and intramuscular injection are described in circulated protocols — IM delivery into the target muscle group is favored by users pursuing a 'local' muscle-growth rationale even though the pegylated form was specifically designed to produce systemic distribution rather than local action. Post-workout timing (within 30–60 minutes) is the most common convention. All of the above is practitioner convention rather than validated dosing. PEG-MGF has no pharmacokinetic characterization in humans, no dose-response curve, and no clinical trial framework to anchor injection timing, frequency, or cycle length. Users should not mistake specificity of numbers for specificity of evidence.

PEG-MGF is not FDA-approved for any indication and has not been tested in controlled human clinical trials. The numbers above reflect research-chemical community practice, not a prescription or a validated protocol. Human safety, efficacy, and pharmacokinetic data are absent.

Timeline of Effects

Onset

User-reported onset of subjective effects — improved workout recovery, reduced post-exercise soreness — is typically described within 1–2 weeks of starting a protocol. These reports are anecdotal and unvalidated by controlled data. No human pharmacokinetic study has characterized actual serum exposure from an injection of synthetic PEG-MGF.

Peak Effect

Anecdotal reports describe peak subjective benefit emerging over 3–6 weeks of consistent dosing. There is no validated human peak-effect timeline; native MGF expression in muscle biopsies peaks within hours to days of a mechanical stimulus, but the dynamics of a pegylated exogenous E-domain peptide are not directly comparable.

After Discontinuation

The pegylated form has an extended half-life relative to native MGF, but published human clearance data does not exist. Theoretically, circulating PEG-MGF would clear over days following discontinuation, with any muscle-biology effects tied to the satellite-cell activation window rather than continued receptor occupancy. No rebound effect has been systematically described, and no suppression of endogenous systems would be expected because the E-domain peptide does not replicate a circulating regulatory hormone.

Common Questions

Should I use MGF or PEG-MGF?

MGF for localized, immediate post-workout effects at specific muscle sites. PEG-MGF for systemic, longer-lasting recovery support. Some protocols combine both. Note that neither has been tested in human clinical trials for these purposes.

Is PEG-MGF banned in sports?

Yes. Mechano growth factors (MGFs) are explicitly named on the 2026 and 2027 WADA Prohibited Lists under S2.3 (growth factors and growth factor modulators), which covers PEG-MGF. Anti-doping labs have developed mass spectrometry methods to detect synthetic MGF.

Has PEG-MGF ever been studied in humans?

No. There is no published clinical trial of PEG-MGF in humans — no pharmacokinetic data, no efficacy trial in any population, and no FDA-registered product. Human research on MGF biology is limited to measuring endogenous MGF mRNA expression in muscle biopsies after resistance exercise. The only related human study tested a pegylated recombinant full-length IGF-1, which is pharmacologically distinct from the PEG-MGF E-domain peptide sold in research-chemical channels.

Does the isolated MGF E-peptide actually activate satellite cells?

It is genuinely contested. Earlier work suggested the E-domain peptide activates muscle satellite cells independently of the IGF-1 receptor, which became the central rationale for commercial use. But a 2014 study by Fornaro and colleagues reported that the isolated E-peptide had no apparent effect on myoblasts or primary muscle stem cells, directly contradicting that premise. The mechanism behind PEG-MGF's marketed effects is unsettled, not established.

Who PEG-MGF Is NOT For

Contraindications
  • •Active or recent-history cancer — and this is no longer purely precautionary. Armakolas and colleagues found that the IGF-1Ec (MGF) transcript is preferentially expressed in cancerous prostate tissue and that administering a synthetic MGF E peptide stimulated the growth of human prostate cancer cells, describing it as an autonomous growth factor activity. That is in vitro work rather than human outcome data, but it is a direct proliferative signal in a malignant human cell line from the exact peptide PEG-MGF is built from, which makes use in active malignancy inappropriate rather than merely unadvisable.
  • •Pregnancy — no human pregnancy safety data exists for PEG-MGF or native MGF. The E-domain peptide's role in development and its theoretical effects on fetal growth have not been characterized in reproductive-toxicology studies.
  • •Breastfeeding — no data on transfer into breast milk or effects on nursing infants.
  • •Pediatric use — development-related signaling effects from exogenous IGF-1 splice variants are not characterized, and pediatric use falls entirely outside any evidence base.
  • •Known hypersensitivity to peptide therapeutics, pegylated compounds, or excipients in compounded preparations — immune reactions against pegylated products have been documented across multiple PEG-conjugated drug classes.
  • •Uncontrolled diabetes or insulin-resistant states — IGF-1-family signaling has metabolic effects that have not been characterized for the pegylated E-domain specifically, and patients with metabolic disease carry additional unknowns.

Drug & Supplement Interactions

Documented clinical drug interactions for PEG-MGF are essentially nonexistent because human pharmacology studies are essentially nonexistent. What follows is theoretical and derived from mechanistic overlap with the IGF-1 family. The most relevant theoretical concern is with IGF-1R-modulating therapies used in oncology: pharmacologic IGF-1R activation by an E-domain fragment, whether direct or indirect, would be expected to oppose the intent of IGF-1R-targeted cancer therapies and to interact with general chemotherapy regimens that depend on intact apoptotic signaling in rapidly dividing cells. Co-administration with anti-angiogenic agents (bevacizumab, VEGF pathway inhibitors) raises concerns because MGF-family signaling includes angiogenic components in preclinical work. Glucose-regulating medications — insulin, sulfonylureas, GLP-1 receptor agonists — warrant attention because IGF-1-family activity influences insulin sensitivity and glucose disposal. The magnitude of any metabolic interaction from PEG-MGF at research-chemical doses is unquantified. Pegylated product concerns include the possibility of anti-PEG antibody formation on repeated exposure, which has been documented with other pegylated pharmaceuticals; this is a class-level concern rather than a PEG-MGF-specific finding. Patients on any regular medication should understand that absence of documented interaction does not equal absence of interaction — it equals absence of data.

Safety Profile

Safety Information

Common Side Effects

Injection site reactionsMild swellingFatigue

Cautions

  • • Not FDA-approved
  • • Very limited human data
  • • PEGylation may alter receptor-binding potency while extending duration
  • • Long-term effects unknown
  • • Listed as prohibited substance by WADA

What We Don't Know

Human safety and efficacy data are essentially nonexistent for PEG-MGF specifically. One study found MGF E-peptide alone had no apparent effect on myoblasts in isolation, raising questions about the mechanism. PEGylation effects on MGF bioactivity and receptor interactions need further characterization.

Myths & Misconceptions

Myth

PEG-MGF is a muscle-building peptide with established efficacy in humans.

Reality

PEG-MGF has no completed human clinical trial of any kind. The muscle-growth narrative is built from Goldspink's expression work on endogenous MGF in exercised muscle, from animal injection studies of native MGF, and from extrapolation — not from controlled data on the pegylated synthetic product. Treating PEG-MGF as a validated muscle-building agent substantially overstates what the evidence supports.

Myth

PEG-MGF works better than native MGF because the pegylation extends its action.

Reality

PEGylation reliably extends plasma half-life for molecules where it has been measured — that is what it is designed to do, and for pegylated full-length IGF-1 the measured figure is 140 to 200 hours. But no half-life has ever been published for PEG-MGF or for native MGF, so the specific 'minutes to hours' upgrade is an assumption rather than a comparison of two measured numbers. But MGF's biological role is as a local, acutely expressed signal in damaged muscle, not as a circulating systemic hormone. Extending the peptide's systemic lifetime may actually move it further away from its native biological context, not closer. 'Longer-lasting' is not axiomatically 'better' for a locally acting signaling peptide.

Myth

The E-domain peptide alone reliably activates satellite cells — that is established biology.

Reality

A published study (Fornaro and colleagues, 2014) reported that the isolated MGF E-peptide had no apparent effect on myoblasts or primary muscle stem cells, directly contradicting earlier findings that had motivated the commercial interest. The current mechanistic picture is contested rather than settled, and any strong claim about E-peptide-driven satellite-cell activation should be read against that uncertainty.

Myth

PEG-MGF is FDA-approved or was in clinical trials.

Reality

PEG-MGF has never been FDA-approved and has never been the subject of a completed clinical trial published in the peer-reviewed literature. A single study of a pegylated recombinant full-length IGF-1 (not the MGF E-domain) exists, but that compound is pharmacologically distinct from PEG-MGF.

Myth

PEG-MGF is undetectable in drug testing because the peptide clears quickly.

Reality

Detection has moved on, and the gap this myth relied on has closed. The 2014 mass-spectrometry method covered full-length MGF, not the short E-peptide forms actually sold, which left room for the argument. Validated initial testing procedures published since then explicitly cover human MGF and MGF-Goldspink — the forms in circulation — in both doping-control urine and blood, at the sensitivity WADA requires. MGF-family compounds are prohibited at all times under WADA S2.3 as non-specified substances, and an anti-doping laboratory that tested peptide confiscated from the market reported the stabilised analogue has good plasma stability, which cuts against the assumption that it clears too fast to catch.

Published Research

22 studies

The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.

The only peer-reviewed paper in the indexed literature that names PEG-MGF at all, and the direct source for two things this page now states: that its half-life is not reported, and that it sits in the review's lowest evidence tier, reserved for compounds with no peer-reviewed human studies whatsoever. It also warns against the inference this page previously made, noting that PEGylation fundamentally alters pharmacokinetics and tissue exposure, so effects seen with native IGF-1Ec or isolated E-domain peptides cannot be assumed to apply to pegylated constructs.

ReviewPMID: 42395176

Chromatographic-mass spectrometric analysis of peptidic analytes (2-10 kDa) in doping control urine samples.

Analytical MethodPMID: 38197510

Impaired Skeletal Muscle Regeneration Induced by Macrophage Depletion Could Be Partly Ameliorated by MGF Injection.

PreclinicalPMID: 31164836

Overexpression of Mechano-Growth Factor Modulates Inflammatory Cytokine Expression and Macrophage Resolution in Skeletal Muscle Injury.

PreclinicalPMID: 30140235

First-in-man study with a novel PEGylated recombinant human insulin-like growth factor-I.

Kletzl et al., Growth Horm IGF Res 2017 — 62 healthy volunteers given RO5046013, and the source of the only measured PEGylation half-life in this literature, 140 to 200 hours. It is included here precisely because that number is the one most likely to be misapplied: RO5046013 is pegylated full-length recombinant human IGF-1, a different molecule from the pegylated E-domain fragment sold as PEG-MGF, and nothing in this study licenses a half-life figure for PEG-MGF.

Randomized Controlled TrialPMID: 28110155

Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.

Analytical MethodPMID: 28035768

Effects of resistance training on expression of IGF-I splice variants in younger and older men.

Clinical StudyPMID: 27231807

Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations.

Janssen and colleagues, PLoS One 2016 — independent receptor pharmacology from Erasmus MC, Charite and the German Sport University, and the study that resolves this page's central ambiguity. Full-length MGF activates IGF-1R to a similar maximum as IGF-1 but about nine-fold less potently (EC50 7.83 vs 0.86 nmol/L) and activates both insulin receptor isoforms, with IR-B stimulation exceeding insulin's. The isolated human E-peptide and its stabilised analogue activated none of them. Since PEG-MGF is built from the E-peptide, this is simultaneously the best reassurance against IGF-1R-driven risk and the strongest evidence that the fragment has no receptor to act through.

PreclinicalPMID: 26991004

Localized delivery of mechano-growth factor E-domain peptide via polymeric microstructures improves cardiac function following myocardial infarction.

PreclinicalPMID: 25678113

Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.

Thevis and colleagues — the paper that retires the undetectability myth with concrete numbers: a 12,264.9 Da analyte detectable at 0.25 ng/mL, implemented into modified routine doping controls. Its scope limitation matters as much as its result, since it characterises full-length MGF rather than the short E-peptide forms actually sold, which is why the later urine and blood methods covering human MGF and MGF-Goldspink are the ones that close the gap.

Analytical MethodPMID: 25466910

Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells (Fornaro et al., Am J Physiol Endocrinol Metab 2014)

The most important paper on this page. Novartis and GSK set out explicitly to reproduce the claimed satellite-cell effect and failed across four assays and three cell types: concentrations up to 500 ng/mL did not increase proliferation of C2C12 cells or primary human myoblasts, the peptide did not inhibit myotube differentiation, primary mouse muscle stem cells showed no response, and neither the native nor a stabilised peptide activated p-ERK in cardiac myocytes. Mature IGF-1 and full-length IGF-1Eb worked as positive controls throughout, so the assays were live. The authors concluded the results call into question whether MGF has a physiological role at all.

PreclinicalPMID: 24253050

Mechano-Growth Factor: an important cog or a loose screw in the repair machinery?

ReviewPMID: 23125840

Age-related loss of muscle mass and strength.

ReviewPMID: 22506111

Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages.

Kandalla, Goldspink, Butler-Browne and Mouly, Mech Ageing Dev 2011 — the positive human-cell result the commercial rationale rests on, tested on primary human muscle cells using the 24-amino-acid E peptide. Two caveats belong with it: Goldspink, who named MGF, is a co-author, so it is not independent of the originating programme; and the effect was present in cells from neonatal and young adult donors but absent in those from old adult muscle, which sits awkwardly with a product marketed for recovery and sarcopenia.

PreclinicalPMID: 21354439

Preferential expression of IGF-1Ec (MGF) transcript in cancerous tissues of human prostate: evidence for a novel and autonomous growth factor activity of MGF E peptide in human prostate cancer cells.

PreclinicalPMID: 20564425

Minireview: Mechano-growth factor: a putative product of IGF-I gene expression involved in tissue repair and regeneration.

Matheny, Nindl and Adamo, Endocrinology 2010 — independent of the originating programme and the single most important caveat in the MGF literature: no analogous peptide product of the IGF-1 gene has been identified in, or isolated from, cultured cells, their conditioned medium, or any in vivo animal tissue or biological fluid. The molecule PEG-MGF is modelled on has never been shown to exist as a discrete natural peptide.

ReviewPMID: 20130113

Mechano-growth factor, an IGF-I splice variant, rescues motoneurons and improves muscle function in SOD1(G93A) mice.

PreclinicalPMID: 19038252

A synthetic mechano growth factor E Peptide enhances myogenic precursor cell transplantation success.

PreclinicalPMID: 17845560

Mechano-growth factor reduces loss of cardiac function in acute myocardial infarction.

PreclinicalPMID: 17581790

Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting.

ReviewPMID: 16463438

A strong neuroprotective effect of the autonomous C-terminal peptide of IGF-1 Ec (MGF) in brain ischemia.

PreclinicalPMID: 16144956

Different roles of the IGF-I Ec peptide (MGF) and mature IGF-I in myoblast proliferation and differentiation.

PreclinicalPMID: 12095637

Quick Facts

Class
PEGylated Growth Factor
Tier
D
Evidence
Preliminary
Safety
Limited Data
Updated
Nov 2026
Citations
22PubMed

Also known as

PEGylated Mechano Growth FactorPEG-MGF E-domain peptide

Tags

Growth FactorMuscle GrowthRecovery

Related Goals

Conditions Discussed

Evidence Score

Overall Confidence25%

Clinical Trials

View Clinical Trials

Links to ClinicalTrials.gov for reference. Listing does not imply endorsement.